Actinogen Medical (ACW) AI Stock Analysis

• Market Cap: AU$73.07M
• Dividend Yield: N/A
• Average Volume (3M): 3.73M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: N/A
• EPS Growth: 49.25%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 3,177,147,200
• 10 Day Avg. Volume: 2,440,705
• 30 Day Avg. Volume: 3,729,168
• PEG Ratio: -0.20
• Price to Book (P/B): 3.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

Actinogen Medical Limited's overall stock score is primarily influenced by strong revenue growth but hindered by negative profitability and cash flow challenges. The technical analysis suggests a neutral to slightly bullish outlook, while the valuation reflects the typical risks of a biotechnology firm with ongoing losses. The lack of earnings call and corporate events data also limits further insights.

Actinogen Medical Business Overview & Revenue Model

Company Description

Actinogen Medical (ACW) is a biotechnology company focused on the development and commercialization of innovative treatments for cognitive impairment and other central nervous system (CNS) disorders. The company's lead product, Xanamem, is a promising drug candidate aimed at treating cognitive decline associated with conditions such as Alzheimer's disease and other neurodegenerative diseases. Actinogen Medical operates primarily in the pharmaceutical and biotechnology sectors, leveraging cutting-edge research to address unmet medical needs in CNS disorders.

How the Company Makes Money

Actinogen Medical makes money primarily through the development and commercialization of its drug candidates, with a focus on Xanamem. The company seeks to generate revenue through the successful clinical development and eventual market approval of Xanamem, which can lead to sales revenue, licensing agreements, and potential partnerships with larger pharmaceutical companies for distribution and marketing. Actinogen may also receive research grants and funding from governmental and non-governmental organizations to support its R&D activities. Additionally, strategic collaborations and partnerships may provide upfront payments, milestone payments, and royalties that contribute to the company's earnings.

Actinogen Medical Financial Statement Overview

Summary

Actinogen Medical Limited shows strong revenue growth but faces challenges with profitability and cash flow management. The company operates with high R&D expenses leading to negative net income and cash flows. Despite these issues, the balance sheet remains stable with low debt levels.

Income Statement

The company shows a consistent increase in total revenue over the years, with a revenue growth rate of 103.2% from 2023 to 2024. Despite this growth, the company has been operating at a loss, evidenced by negative net income and EBIT margins. Gross profit margin remains strong as the cost of goods sold is negligible, but the high operating expenses lead to negative EBIT and net profit margins.

Balance Sheet

Stockholders' equity has increased over the years, indicating capital growth. The debt-to-equity ratio is very low, suggesting that the company is not heavily reliant on debt. However, the consistent negative net income impacts the return on equity negatively. The equity ratio is strong, highlighting financial stability with significant equity compared to total assets.

Cash Flow

The company has a negative operating cash flow, which has increased in magnitude, indicating higher cash burn. Though the company has managed to raise financing cash flow to cover its cash needs, free cash flow remains negative. The operating cash flow to net income ratio is concerning, reflecting inefficiencies in converting revenue to cash.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	9.93M	4.89M	3.64M	1.98M	3.52M
Gross Profit	9.93M	4.48M	3.24M	1.60M	3.10M
EBITDA	-12.92M	-15.22M	-12.72M	-5.35M	-8.20M
Net Income	-13.04M	-10.75M	-9.50M	-3.92M	-5.33M
Balance Sheet
Total Assets	21.31M	15.21M	23.31M	18.38M	11.94M
Cash, Cash Equivalents and Short-Term Investments	9.45M	8.46M	16.37M	13.42M	5.04M
Total Debt	319.07K	86.93K	165.27K	236.44K	389.87K
Total Liabilities	1.62M	1.80M	1.57M	920.32K	1.05M
Stockholders Equity	19.70M	13.41M	21.74M	17.46M	10.89M
Cash Flow
Free Cash Flow	-16.96M	-8.73M	-9.52M	-1.73M	-2.88M
Operating Cash Flow	-16.95M	-8.70M	-9.52M	-1.72M	-2.86M
Investing Cash Flow	-8.16K	-36.60K	-2.94K	-6.19K	-22.76K
Financing Cash Flow	17.95M	824.62K	12.42M	10.11M	282.26K

Actinogen Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.03
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACW, the sentiment is Positive. The current price of 0.03 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.48 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ACW.

Actinogen Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EZZ	76 Outperform	AU$104.25M	11.43	45.86%	1.81%	71.65%	152.89%
PTX	56 Neutral	AU$33.82M	―	-36.95%	―	―	11.11%
ACW	52 Neutral	AU$73.07M	―	-55.44%	―	―	49.25%
Sector *	50 Neutral	AU$2.51B	3.43	-57.47%	2.67%	36.73%	13.67%
ATH	49 Neutral	$100.40M	―	-154.88%	―	―	20.00%
ALA	40 Underperform	AU$124.80M	―	-85.35%	―	315.11%	51.16%
RAD	34 Underperform	AU$52.03M	―	-108.26%	―	―	53.41%

Actinogen Medical Corporate Events

Actinogen Medical Secures $13.8 Million in Non-Dilutive Funding to Advance Alzheimer’s Trial

Actinogen Medical has secured up to $13.8 million in non-dilutive funding through a Research and Development Tax Incentive, with an initial $3 million received and further amounts contingent on future approvals. This funding will support the ongoing XanaMIA phase 2b/3 Alzheimer’s disease trial and general working capital, strengthening the company’s financial position as it progresses toward key milestones, including interim analysis of its clinical trial.

Actinogen Medical Advances Alzheimer’s Trial with Key Milestone

Actinogen Medical has reached a significant milestone in its XanaMIA phase 2b/3 trial for Alzheimer’s disease by enrolling its 100th participant, setting the stage for an interim analysis of safety and efficacy data. This analysis, conducted by an independent Data Monitoring Committee, will occur in January 2026, with final trial results expected in late 2026. The trial aims to demonstrate the safety and efficacy of Xanamem, potentially expediting its regulatory approval. The company is also preparing for discussions with the US FDA regarding approval pathways and may seek commercial partnerships for the next phase of development.

BVF Partners Ceases Substantial Holding in Actinogen Medical

Actinogen Medical Limited has announced that BVF Partners L.P., along with its affiliates, has ceased to be a substantial holder in the company. This development follows a series of on-market sales of fully paid ordinary shares by BVF Partners and its associates, which took place between April 22 and May 19, 2025. The divestment of shares by BVF Partners may impact Actinogen Medical’s shareholder composition and could influence market perceptions of the company’s stock.

Actinogen’s Xanamem Shows Promise in Depression Treatment

Actinogen Medical announced positive results from a Phase 2 trial of its drug Xanamem, presented at the American Psychiatric Association’s 2025 meeting. The trial demonstrated that a 10 mg dose of Xanamem significantly improves symptoms of moderate Major Depressive Disorder, validating its mechanism of controlling brain cortisol levels. These findings not only highlight Xanamem’s potential as an effective antidepressant with a unique mechanism of action but also support its use in ongoing trials for Alzheimer’s Disease. The promising safety profile and durability of Xanamem’s benefits position it as a competitive candidate in the antidepressant market, potentially benefiting patients with Alzheimer’s who also suffer from depression.

Actinogen Medical Advances Alzheimer’s Treatment with Xanamem

Actinogen Medical announced a panel discussion featuring key company figures and experts to discuss advancements in Alzheimer’s treatments and the commercialization of Xanamem, their novel oral medication. The company is actively preparing for commercialization by designing pivotal trials, developing thought leaders, and refining communication strategies, which are crucial for maximizing future partnerships and addressing the significant unmet medical need for effective Alzheimer’s therapies.

Actinogen Medical Advances Alzheimer’s and Depression Trials with Regulatory and Manufacturing Milestones

Actinogen Medical has made significant progress in its XanaMIA phase 2b/3 clinical trial for Alzheimer’s disease, with accelerated patient screening and enrollment across multiple sites in the US and Australia. The company also achieved a successful regulatory meeting with the FDA regarding major depressive disorder, marking a major accomplishment that could enhance future partnerships and funding opportunities. Additionally, the World Health Organization granted a unique name to Xanamem, recognizing its novel mechanism of action, and the company continues to advance its manufacturing and strategic planning efforts.

Actinogen Medical Prepares for Xanamem Commercialization with Upcoming Forum

Actinogen Medical announced an upcoming Clinical Trials Science Forum to discuss advancements in Alzheimer’s treatments and the commercialization of Xanamem, their novel oral medication. The forum will highlight the company’s strategic planning for commercialization, including trial designs and stakeholder engagement, which are crucial for maximizing future partnerships and addressing the unmet need for effective Alzheimer’s therapies.

Actinogen Medical Sees Change in Substantial Holder’s Voting Power

Actinogen Medical Limited has seen a change in the interests of its substantial holder, BVF Partners L.P., which has reduced its voting power from 7.29% to 6.24% through a series of on-market sales of fully paid ordinary shares. This change in holdings may impact Actinogen’s market position and shareholder dynamics, as BVF Partners L.P. adjusts its investment strategy in the company.